FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer ...

Retrieved on: 2024-09-16 04:17:24

Tags for this article:

Orphan drugs

Atezolizumab

Subcutaneous administration

u.s. food and drug administration

Click the tags to see associated articles and topics

FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer .... View article details on hiswai:

Excerpt

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first ...

Article found on: www.indianpharmapost.com

View Original Article